Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Fatty liver more common in MAFLD than NAFLD
Patients with metabolic dysfunction-associated fatty liver disease (MAFLD) see higher rates of fatty liver than those with nonalcoholic fatty liver disease (NAFLD), a recent study has found.
Fatty liver more common in MAFLD than NAFLD
03 Dec 2022
LSM improves prediction of cholangitis outcomes
Liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) is independently associated with primary biliary cholangitis (PBC) outcomes, a study has shown.
LSM improves prediction of cholangitis outcomes
28 Nov 2022
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
A recent study has demonstrated the safety and efficacy of bulevirtide (BLV) monotherapy for 48 weeks in difficult-to-treat patients with hepatitis delta virus (HDV)-related compensated cirrhosis and clinically significant portal hypertension (CSPH).
Bulevirtide safe, effective in HDV-induced cirrhosis with hypertension
27 Nov 2022
Which factors raise HCC risk in patients with cured HCV?
Predictors of hepatocellular carcinoma (HCC) differ in patients with virologically cured hepatitis C virus (HCV) infection with and without cirrhosis, according to a study. However, changes in fibrosis-4 (FIB-4) scores over time are associated with HCC risk in both cohorts.
Which factors raise HCC risk in patients with cured HCV?
24 Nov 2022
Entecavir plus traditional Chinese medicine cuts HCC risk in CHB
Among patients with chronic hepatitis B (CHB), treatment with entecavir (ETV) and Biejia-Ruangan compound (BRC), an antifibrotic traditional Chinese medicine, helps reduce the risk of hepatocellular carcinoma (HCC), a recent study reports.